In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .
Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome
Objective To evaluate the safety and preliminary pharmacokinetics of a pharmaceutical formulation of purified cannabidiol ( CBD ) in children with Dravet syndrome . Methods Patients aged 4–10 years were r and omized 4:1 to CBD ( 5 , 10 , or 20 mg/kg/d ) or placebo taken twice daily . The double-blind trial comprised 4-week baseline , 3-week treatment ( including titration ) , 10-day taper , and 4-week follow-up periods . Completers could continue in an open-label extension . Multiple pharmacokinetic blood sample s were taken on the first day of dosing and at end of treatment for measurement of CBD , its metabolites 6-OH-CBD , 7-OH-CBD , and 7-COOH-CBD , and antiepileptic drugs ( AEDs  ; clobazam and metabolite N-desmethylclobazam [ N-CLB ] , valproate , levetiracetam , topiramate , and stiripentol ) . Safety assessment s were clinical laboratory tests , physical examinations , vital signs , ECGs , adverse events ( AEs ) , seizure frequency , and suicidality . Results Thirty-four patients were r and omized ( 10 , 8 , and 9 to the 5 , 10 , and 20 mg/kg/d  CBD  groups , and 7 to placebo )  ; 32 ( 94 % ) completed treatment . Exposure to CBD and its metabolites was dose-proportional ( AUC0–t ) . CBD did not affect concomitant AED levels , apart from an increase in N-CLB ( except in patients taking stiripentol ) . The most common AEs on CBD were pyrexia , somnolence , decreased appetite , sedation , vomiting , ataxia , and abnormal behavior . Six patients taking CBD and valproate developed elevated transaminases ; none met criteria for drug-induced liver injury and all recovered . No other clinical ly relevant safety signals were observed . Conclusions Exposure to CBD and its metabolites increased proportionally with dose . An interaction with N-CLB was observed , likely related to CBD inhibition of cytochrome P450 subtype 2C19 . CBD result ed in more AEs than placebo but was generally well-tolerated . Classification of evidence This study provides Class I evidence that for children with Dravet syndrome , CBD result ed in more AEs than placebo but was generally well-tolerated
In both rodent and cell culture models , CBD was found to exert a neuroprotective effect against adverse alcohol consequences on the hippocampus .
In rodent models , CBD was found to attenuate alcohol-induced hepatotoxicity , specifically , alcohol-induced steatosis .
Finally , findings from pre clinical rodent models also indicate that CBD attenuates cue-elicited and stress-elicited alcohol seeking , alcohol self-administration , withdrawal-induced convulsions , and impulsive discounting of delayed rewards .
In human studies , CBD was well tolerated and did not interact with the subjective effects of alcohol .
Collectively , given its favorable effects on alcohol-related harms and addiction phenotypes in pre clinical models , CBD appears to have promise as a c and i date AUD pharmacotherapy .
This is further bolstered by the absence of abuse liability and its general tolerability .
There is substantial interest in the therapeutic potential of cannabidiol ( CBD ) , a nonpsychoactive cannabinoid found in plants of the genus Cannabis .
The goal of the current systematic review was to characterize the existing literature on this topic and to evaluate the credibility of CBD as a c and i date pharmacotherapy for alcohol use disorder ( AUD ) .